Amalgamated Bank Has $108,000 Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Amalgamated Bank lessened its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 7.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,790 shares of the biotechnology company’s stock after selling 1,920 shares during the quarter. Amalgamated Bank’s holdings in ADMA Biologics were worth $108,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. raised its stake in shares of ADMA Biologics by 31.3% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 15,000 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 3,572 shares in the last quarter. Sawgrass Asset Management LLC bought a new stake in shares of ADMA Biologics in the third quarter valued at approximately $55,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of ADMA Biologics during the 3rd quarter worth $58,000. Commonwealth Equity Services LLC grew its stake in ADMA Biologics by 61.8% during the third quarter. Commonwealth Equity Services LLC now owns 16,360 shares of the biotechnology company’s stock worth $59,000 after buying an additional 6,250 shares in the last quarter. Finally, Algert Global LLC bought a new position in ADMA Biologics in the third quarter valued at approximately $80,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $9.56 on Friday. ADMA Biologics, Inc. has a fifty-two week low of $3.06 and a fifty-two week high of $9.77. The stock’s 50 day simple moving average is $7.04 and its two-hundred day simple moving average is $5.54. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.86 and a current ratio of 5.21. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -478.00 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.03. The firm had revenue of $81.90 million during the quarter, compared to analyst estimates of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The business’s revenue was up 43.9% on a year-over-year basis. During the same period last year, the business earned ($0.03) earnings per share. As a group, analysts expect that ADMA Biologics, Inc. will post 0.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ADMA shares. HC Wainwright upped their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Raymond James raised their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a research report on Friday, May 10th. Mizuho increased their price objective on ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, May 10th. Finally, Cantor Fitzgerald boosted their price objective on ADMA Biologics from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Friday, May 10th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $10.50.

Insider Buying and Selling

In other news, Director Steve Elms sold 407,000 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total transaction of $2,527,470.00. Following the completion of the sale, the director now owns 3,208,671 shares of the company’s stock, valued at approximately $19,925,846.91. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 639,895 shares of company stock worth $3,927,169. 3.70% of the stock is owned by insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.